Oncology and the "Standard of Care" in the US Biosimilars...

added blog Health

2026-04-02 12:11:37 -

Oncology and the "Standard of Care" in the US Biosimilars Market

Cancer care in America has become the "Gold Standard" for biosimilar success this year. In 2026, the US Biosimilars Market is dominated by the oncology segment, which accounts for over 26% of total revenue. Biosimilars for major cancer treatments like bevacizumab, trastuzumab, and rituximab have reached a market share of nearly 80% in many hospital systems. This widespread adoption is primarily...

0 Comments 0 Shares 70 Views 0 Reviews